R&D 저희 회사를 소개합니다.

    Major achievements

    • Formulation
      8Formulation

      Hypertension : AD-107
      Antithrombotic : AD-109
      Ulcer treatment : AD-215
      Diabetes mellitus : AD-219
      Hyperlipidemia : AD-220 and 3projects

    • Phase 1
      20Phase 1

      Hypertension : AD-210 and 3projects
      Ulcer treatment & GERD : AD-212 and 5projects
      Diabetes mellitus : AD-204, PA-108
      Hyperlipidemia : AD-205 and 5projects
      Pain treatment : AD-211, PA-105

    • Phase 2
      1Phase 2

      Hypertension : AD-209

    • Phase 3
      3Phase 3

      Hyperlipidemia / Hypertension :
      AD-202, AD-207
      Alopecia : AD-208

    • MA
      7MA

      Postmenopausal osteoporosis : AD-101, AD-102
      Ulcer treatment : AD-203, AD-206
      Hyperlipidemia : AD-201, AD-103, AD-104
      Alopecia : AD-106

    Major accomplishments

    2020
    • 12

      AD-203 (Ulcer treatment) : Approved

    • 11

      AD-104 (Hyperlipidemia) : Approved

      AD-102 (Postmenopausal osteoporosis) : MA Filed on Nov, 2020

    • 10

      AD-201 (Hyperlipidemia / Hypertension) : Phase 3 Completed

      AD-102 (Postmenopausal osteoporosis) : Bioequivalence confirmed

      AD-106 (Alopecia) : Bioequivalence confirmed

      PA-101 (Postmenopausal osteoporosis) : Bioequivalence confirmed

    • 09

      AD-206 (GERD) : MA Filed on Sep, 2020

    • 07

      AD-203 (Ulcer treatment) : Filed on Jul, 2020

      AD-202 (Hyperlipidemia / Hypertension) : Bioequivalence confirmed

      AD-206 (GERD) : Bioequivalence confirmed

    • 06

      AD-201 (Hyperlipidemia / Hypertension) : Bioequivalence confirmed

    • 05

      AD-207 (Hyperlipidemia / Hypertension) : Bioequivalence confirmed

    • 04

      AD-104 (Hyperlipidemia) : Bioequivalence confirmed

    • 03

      AD-103 (Hyperlipidemia) : Bioequivalence confirmed

    2019
    • 09

      AD-101 (Postmenopausal osteoporosis) : Approved